Q2 2024 Travere Therapeutics Inc Earnings Call Transcript

Aug 01, 2024 / 08:30PM GMT

Release Date Price: $9.24 (-3.14%)

Transcript 10-Q8-K

Key Points

Positve

FILSPARI is becoming a foundational therapy for IgA nephropathy, showing strong demand and revenue growth.
The company achieved a 37% increase in FILSPARI sales in the second quarter, positioning it to outperform recent rare nephrology revenue benchmarks.
Travere Therapeutics Inc (TVTX) has strong payer coverage with 96% of US lives having a pathway to FILSPARI reimbursement.
The company is preparing for potential full approval of FILSPARI, which could broaden its label and increase the addressable patient population.
Travere Therapeutics Inc (TVTX) has reduced operating cash use and expects further declines, supporting operations into 2028.

Negative

The company reported a net loss of $70.4 million for the second quarter of 2024.
There is uncertainty regarding the modification or removal of REMS requirements for FILSPARI, which could impact its market potential.
The eGFR endpoint was not achievable in the Phase 3 DUPLEX trial for FSGS, indicating challenges in demonstrating long-term kidney function preservation.
The company faces competition from upcoming complement inhibitors and B cell agents in the IgA nephropathy treatment landscape.
The conversion of patient start forms to actual prescriptions has been slower than expected, impacting the speed of revenue realization.

Operator

Good day, and welcome to the Travere Therapeutics second quarter 2024 financial results and corporate update conference call. Today's call is being recorded.

At this time, I would like to turn the conference call over to the Vice President of Corporate Communications and Investor Relations, Nivi Nehra. Please go ahead, Nivi.

Nivi Nehra

Travere Therapeutics Inc - Vice President, Head of Corporate Communications

Thank you, Rachel. Good afternoon and welcome to Travere Therapeutics second quarter 2024 financial results and corporate update call. Thank you all for joining. Today's call will be led by our President and Chief Executive Officer, Dr. Eric Dube. Eric will be joined in the prepared remarks by Dr. Jula Inrig, our Chief Medical Officer; Peter Heerma, our Chief Commercial Officer; and Chris Cline, our Chief Financial Officer. Dr. Bill Rote, Senior Vice President of Research and Development will join us for the Q&A session.

Before we begin, I'd like to remind everyone that statements made during this call regarding matters that are

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.